Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ginkgo Bioworks
DNA
|
+$1.11B |
| 2 |
Peloton Interactive
PTON
|
+$877M |
| 3 |
Coupang
CPNG
|
+$455M |
| 4 |
DoorDash
DASH
|
+$423M |
| 5 |
Spotify
SPOT
|
+$387M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$2.87B |
| 2 |
Tesla
TSLA
|
+$1.41B |
| 3 |
Moderna
MRNA
|
+$1.35B |
| 4 |
Amazon
AMZN
|
+$928M |
| 5 |
NetEase
NTES
|
+$766M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 27.57% |
| 2 | Healthcare | 26.02% |
| 3 | Technology | 18.64% |
| 4 | Communication Services | 12.04% |
| 5 | Financials | 5.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Celsius Holdings
CELH
$7.03B
| $23K | ﹤0.01% |
780
| – | – |
|
352
W.W. Grainger
GWW
$60.2B
| $23K | ﹤0.01% |
+59
| New | +$25.6K |
|
353
ON Semiconductor
ON
$31.6B
| $23K | ﹤0.01% |
+500
| New | +$21.4K |
|
354
PagerDuty
PD
$902M
| $23K | ﹤0.01% |
567
-48
| -8% | -$2.03K |
|
|
NVTA
355
DELISTED
Invitae Corporation
NVTA
| $23K | ﹤0.01% |
+800
| New | +$23.4K |
|
356
BioCryst Pharmaceuticals
BCRX
$2.4B
| $22K | ﹤0.01% |
+1,500
| New | +$23.7K |
|
357
Cohu
COHU
$2.5B
| $22K | ﹤0.01% |
+700
| New | +$23.8K |
|
358
Humana
HUM
$46.2B
| $22K | ﹤0.01% |
56
-2
| -3% | -$849 |
|
359
Knowles
KN
$3.34B
| $22K | ﹤0.01% |
+1,200
| New | +$23.5K |
|
360
Pfizer
PFE
$153B
| $22K | ﹤0.01% |
+500
| New | +$22.1K |
|
361
Progyny
PGNY
$2.2B
| $22K | ﹤0.01% |
396
| – | – |
|
362
XPEL
XPEL
$1.38B
| $22K | ﹤0.01% |
295
-47
| -14% | -$3.87K |
|
|
SGEN
363
DELISTED
Seagen Inc. Common Stock
SGEN
| $22K | ﹤0.01% |
128
| – | – |
|
|
ZNGA
364
DELISTED
ZYNGA INC. CL A COMMON
ZNGA
| $22K | ﹤0.01% |
2,863
-564
| -16% | -$5.12K |
|
365
Boston Omaha
BOC
$436M
| $21K | ﹤0.01% |
529
| – | – |
|
366
Quest Diagnostics
DGX
$26.3B
| $21K | ﹤0.01% |
145
-15
| -9% | -$2.19K |
|
367
Logitech
LOGI
$15.2B
| $21K | ﹤0.01% |
235
-30
| -11% | -$3.24K |
|
368
Medifast
MED
$141M
| $21K | ﹤0.01% |
110
-19
| -15% | -$4.67K |
|
369
Nutanix
NTNX
$16.9B
| $21K | ﹤0.01% |
563
-58
| -9% | -$2.19K |
|
|
SMAR
370
DELISTED
Smartsheet Inc.
SMAR
| $21K | ﹤0.01% |
311
-42
| -12% | -$3.09K |
|
|
MNTV
371
DELISTED
Momentive Global Inc. Common Stock
MNTV
| $21K | ﹤0.01% |
1,095
| – | – |
|
|
GBT
372
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $21K | ﹤0.01% |
835
-119
| -12% | -$3.5K |
|
373
Aptiv
APTV
$10.3B
| $20K | ﹤0.01% |
134
-15
| -10% | -$2.34K |
|
|
VISN
374
Vistance Networks Inc
VISN
$2.52B
| $20K | ﹤0.01% |
1,442
-101
| -7% | -$1.74K |
|
375
Quaker Houghton
KWR
$2.92B
| $20K | ﹤0.01% |
86
| – | – |
|
Similar funds
Baillie Gifford & Co's Q3 2021 Portfolio in Review
As of Q3 2021, Baillie Gifford & Co held 509 positions worth $191B, down 6.8% from $205B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Baillie Gifford & Co's Q3 2021 filing shows 38 new, 113 increased, 204 reduced and 17 closed positions. Its largest new stake was Ginkgo Bioworks: 2,275,070 shares worth $1.05B. The largest sale was Alibaba, an estimated $2.87B.
By sector, the portfolio is most concentrated in Consumer Discretionary at 28% of assets, down from 29% a quarter earlier, followed by Healthcare and Technology.
- Baillie Gifford & Co's largest Q3 2021 buy was Ginkgo Bioworks: 2,275,070 shares worth $1.05B.
- Baillie Gifford & Co added most to Peloton Interactive in Q3 2021, an estimated $877M increase.
- Baillie Gifford & Co's biggest Q3 2021 reduction was Alibaba, cutting an estimated $2.87B.
- Baillie Gifford & Co fully exited EOG Resources in Q3 2021, selling an estimated $329M.
- Baillie Gifford & Co's ten largest holdings make up 40% of its $191B portfolio in Q3 2021.
- Baillie Gifford & Co opened 38 new positions and closed 17 in Q3 2021.
- Baillie Gifford & Co's portfolio value fell 6.8% quarter-over-quarter to $191B.
Based on Baillie Gifford & Co's 13F filing for Q3 2021, filed 19 Oct 2021.